Loading…

HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood

Here, we evaluated innate and adaptive immune system cytokine responses induced by HPV-16 L1 VLP in whole blood (WB) cultures from individuals receiving the vaccine ( n = 20) or placebo ( n = 4) before and after vaccination. 11 cytokines were measured: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2005-05, Vol.23 (27), p.3555-3564
Main Authors: Pinto, Ligia A., Castle, Philip E., Roden, Richard B., Harro, Clayton D., Lowy, Douglas R., Schiller, John T., Wallace, Dora, Williams, Marcus, Kopp, William, Frazer, Ian H., Berzofsky, Jay A., Hildesheim, Allan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Here, we evaluated innate and adaptive immune system cytokine responses induced by HPV-16 L1 VLP in whole blood (WB) cultures from individuals receiving the vaccine ( n = 20) or placebo ( n = 4) before and after vaccination. 11 cytokines were measured: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IFN-γ, TNF-α, and GM-CSF using multiplex bead arrays. Cytokine profiles from WB samples clearly discriminated between vaccine and placebo recipients and between pre and post-vaccination responses. Significant increases in Th1, Th2 and inflammatory cytokines were observed in WB assays following vaccination. Results from WB assays were compared against parallel PBMC-based assays in a subset of patients. Differences between whole blood assay and PBMC were observed, with the highest levels of induction found for WB for several cytokines. Our results indicate that multiplex assays for cytokine profiling in WB are an efficient tool for assessing broad spectrum, innate and adaptive immune responses to vaccines and identifying immunologic correlates of protection in efficacy studies.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2005.01.146